ResMed price target raised to $283 from $280 at Baird

Baird analyst David Rescott raised the firm’s price target on ResMed (RMD) to $283 from $280 and keeps an Outperform rating on the shares. The firm said they’re increasingly confident in likely upside, as market growth remains stable, the company maintains and in some cases gains share, and benefits from expanding AirSense 11 roll-out.